Maravai LifeSciences Holdings Inc. Class A Common Stock vs Quanta Services Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Quanta Services Inc trades at $650.02 (market cap $103.57B). The key difference: Quanta Services Inc is far larger — about 106.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Quanta Services Inc pays a 0.06% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Quanta Services Inc for 62 Days on average.
| MRVI | PWR | |
|---|---|---|
Market Cap | $972.90M | $103.57B |
Volume | 4,325,710 | 1,036,513 |
Sector | Health | Industrials |
52-Week High | $9.00 | $785.24 |
52-Week Low | $2.83 | $412.21 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $1.08B | $109.67B |
Dividend Yield | — | 0.06% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PWR trades at $660.53, down 4.93% for the day, but maintains strong analyst support with 27 buy ratings and a $802.08 consensus price target. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.24 surpassing expectations by 28%. Technical indicators show a bullish trend with support at $682 and resistance at $706. Revenue growth remains robust, climbing from $17.1B in 2022 to $28.5B in 2025.
PWR presents a compelling growth story with strong earnings momentum and a record $53B backlog supporting future revenue. However, elevated valuation ratios (P/E 78.82, EV/EBITDA 35.6) and negative cash flow trends pose risks. The stock offers 21% upside to consensus targets, but investors should weigh premium valuation against execution risks in large infrastructure projects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →